spacer
home > white papers > Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models - DrugDev
WHITE PAPERS
logo_DrugDevd.jpg

DrugDev

phone +1 888 650 1860
email solutions@drugdev.com
web http://www.drugdev.com/
email 1170 Devon Park Drive Suite 300, Wayne, PA 19087

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality.

One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Blood Tests May Prevent Relapse in Breast Cancer Patients

The Royal Marsden NHS Foundation Trust is leading an international research collaboration to offer blood tests that can identify risk of relapse in breast cancer patients. The trial will assess whether personalised blood tests can show which patients will relapse, years before it’s shown on a scan - treatment can then be altered to try and prevent relapse from happening. There are currently no effective tests to establish which patients are at risk of relapse after previous treatment for breast cancer.
More info >>


White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement